TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06637748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiography
Description: Standard 12-lead ECG recording~• Parameters assessed:~* Heart rate and rhythm~* P-wave morphology~* PR interval~* QRS complex duration and morphology~* ST-segment changes~* T-wave abnormalities~* QT interval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiography
Description: Standard 12-lead ECG recording~• Parameters assessed:~* Heart rate and rhythm~* P-wave morphology~* PR interval~* QRS complex duration and morphology~* ST-segment changes~* T-wave abnormalities~* QT interval
Study: NCT06636955

Intervention type: OTHER
Intervention: biobank
Description: * nasopharyngeal swab collection~* nasopharyngeal nasal washes collection, during hospitalization, if any

Intervention type: OTHER
Intervention: biobank
Description: * nasopharyngeal swab collection~* nasopharyngeal nasal washes collection, during hospitalization, if any

Intervention type: OTHER
Intervention: follow up
Description: - one year follow up: after 1 month, 3 months, 6 months et 12 months

Intervention type: OTHER
Intervention: follow up
Description: - one year follow up: after 1 month, 3 months, 6 months et 12 months
Study: NCT06639295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous (SC) injection.
Study: NCT06640127

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lifting and implant placement with osteotomes
Description: Osteotomes with increasing diameters were used for sinus membrane elevation and implant insertion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus lifting and implant placement with specifically designed drills
Description: Sequential drills were used for sinus membrane elevation and implant insertion
Study: NCT06638034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy
Description: Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
Study: NCT06640270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Treatment
Description: Lucie™ is an innovative medical device for measurement by bio-impedancemetry. It has been developed specifically to meet medical needs in nephrology. The aim of the study is to compare its performance with a reference device validated in nephrology nephrology, the Body Composition Monitor® (BCM) from Fresenius.
Study: NCT06488365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytophone
Description: The Cytophone clinical prototype incorporates two pulse lasers, optical system for delivery of laser light to the skin, ultrasound transducer array and detection electronics for acquisition of acoustic waves from CTCs.~Parameters of lasers:~C-Wedge 1064 (Bright Solutions, Cura Carpignano (PV), Italy): Wavelength,1064 nm; pulse width, 0.6 ns; pulse rate: 1 kHz; pulse energy, 240 μJ.~C-Wedge 18901 (Bright Solutions, Cura Carpignano (PV), Italy):~Wavelength, 770 nm; pulse width 3 ns; pulse rate, 1 kHz; pulse energy, 240 μJ. Detection of acoustic waves from CTCs is performing by a focused ultrasound transducer array placed in an acoustic contact with the skin of the subject with ultrasound gel. The signals from the transducers are amplified with a 16 channel amplifier, then digitized by a 12-bit, 500 MSPS high speed board digitizer (ATS9350, AlazarTech, Canada). This information is then transferred to a data recording system using a secure computer.
Study: NCT05598528

Intervention type: OTHER
Intervention: Genomic profiles detection
Description: The Paraffin-embedded tumor tissue at diagnosis is collected and assessed by Next- generation gene sequencing

Intervention type: OTHER
Intervention: circulating tumor DNA detection
Description: The Plasma at diagnosis and at 1-month treatment are collected and assessed by Next-generation gene sequencing
Study: NCT05512390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-319
Description: Intravenous (IV); Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-319
Description: Intravenous (IV); Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-319
Description: Intravenous (IV); Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-319
Description: Intravenous (IV); Infusion
Study: NCT06287736

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulator Implantation (SCS)
Description: Spinal cord stimulator implantation is broken up into two parts. The first part involves placement of temporary SCS leads for a one-week trial. If the participants respond favorably to the SCS, then they will undergo the second part and the device is implanted
Study: NCT06628973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social prescribing
Description: The intervention consists of SP, wherein patients identified as having significant SDOH-related vulnerabilities on the SPARK questionnaire or during an interview will have a consultation with a LW who will provide them with social prescriptions. LWs are individuals who LINK individuals with social needs to existing community supports and services within the community
Study: NCT06489249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate 750 MG Oral Tablet [DISALCID]
Description: Oral salsalate tablet
Study: NCT05947058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Description: The type of hip prothesis (hemi or total; cemented or uncemented) will be at the discretion of the treating surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Fixation
Description: Both fixed angle devices and multiple screws will be permitted for the internal fixation group.
Study: NCT06181396

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Native oxytocin analog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Native oxytocin analog
Study: NCT06641583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEGO
Description: The LEGO Therapy intervention in this clinical trial is designed to enhance social skills in children with high-functioning Autism Spectrum Disorder (ASD). The intervention involves the following components:~Group Sessions: The therapy will be conducted in small groups of three children of the same age (10-14 years) with a diagnosis of high-functioning ASD. The sessions are designed to foster collaboration and social interaction between the participants.~Duration: The intervention will last for 3 months, consisting of 12 sessions, with each session lasting 90 minutes. Sessions will take place once a week at the IRCCS Fondazione Stella Maris.~Supervision: The groups will be supervised by trained professionals specializing in neurodevelopmental disorders, ensuring that the therapy is structured and supportive of each child\&amp;amp;amp;#39;s individual needs.~Therapy Structure: During the sessions, children will engage in LEGO-based tasks, where they collaborate to build LEGO models.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controllo
Description: This group will also consist of children aged 10-14 diagnosed with high-functioning ASD. However, these children will not receive LEGO therapy. Instead, they will continue their usual treatments in their local settings without participating in the LEGO therapy sessions. This group\&#39;s outcomes will be compared with the experimental group to assess the effectiveness of LEGO therapy.
Study: NCT05998993

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy SBRT
Description: This is a non-randomized Phase II study in which all patients receive the experimental treatment with Stereotactic Ablative Radiotherapy (SABR) to residual tumor lesions (up to 5 residual metastatic lesions in a maximum of 2 organs) following 12 weeks of systemic treatment with Osimertinib. The study aims to enroll 35 patients diagnosed and treated at CTIC Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo.
Study: NCT06640153

Intervention type: DIAGNOSTIC_TEST
Intervention: mpMRI
Description: Gastroesophageal junction or upper gastric adenocarcinoma patients undergo mpMRI at siewert classification, length of esophageal involvement, primary staging and restaging
Study: NCT06643429

Intervention type: DIAGNOSTIC_TEST
Intervention: colorectal cancer
Description: Patients diagnosed with colorectal cancer by pathological biopsy.

Intervention type: DIAGNOSTIC_TEST
Intervention: colorectal neoplasm
Description: Patients diagnosed with colorectal adenoma confirmed by colonoscopy.
Study: NCT05935150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omit SLNB
Description: All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.
Study: NCT06644313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vebreltinib
Description: Neoadjuvant treatment stage: Vebreltinib 200mg, bid, po, 2-4 months in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Vebreltinib 200mg, bid, po, up to 2 years/until the disease progressed. PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
Study: NCT04981145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod Tablets
Description: Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
Study: NCT06184269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1017-1
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1017-1A
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1017-1B
Description: One tablet administered alone
Study: NCT05689099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B, 1.34 mg/mL
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B, 1.34 mg/mL
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B, 0.68 mg/mL
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B, 0.68 mg/mL
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
Study: NCT06469242

Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A multifocal contact lenses
Description: Investigational multifocal soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A multifocal contact lenses
Description: Investigational multifocal soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A multifocal contact lenses
Description: Commercially available multifocal soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A multifocal contact lenses
Description: Commercially available multifocal soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE® Cleaning & Disinfecting Solution
Description: Hydrogen peroxide-based contact lens cleaning and disinfection system

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE® Cleaning & Disinfecting Solution
Description: Hydrogen peroxide-based contact lens cleaning and disinfection system
Study: NCT06296225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Grip strenght measurement will always be done in the same way : for each series, 3 measurements of maximum strength will be taken for each side. Participants will receive verbal encouragement.~After initial both sides grip strength evaluation, all participant will first experiment the vibration situation using the device Vibramoov Physio (TechnoConcept, Manosque, France): the vibrations had a frequency of 100Hz, with an amplitude of 2mm, they will be applied to the anterior part of the forearm for 10 minutes, 3 times. At the end of each 10 minutes vibration session, handgrip strength will be assessed.~* Participants then have a one-hour rest period.~* Control situation: participants will have 4 series of grip strength measurements every 10 minutes.~At the end of the 2 hours, the patient will be discharged from the study protocol.
Study: NCT05941429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano-Silver Fluoride
Description: NSF is a varnish which has been introduced as experimental formulation . the laboratory synthesis of NSF was carried out in a nano techonolgy center .
Study: NCT06499506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Below knee amputation
Description: trans tibial amputation one hand breadth below tibial tuberosity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Below knee amputation
Description: trans tibial amputation one hand breadth below tibial tuberosity
Study: NCT05941429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine fluoride
Description: 38% silver diamine fluoride
Study: NCT06636006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 50 continuous minutes, at moderate intensity (Identified by the Borg Subjective Perception of Exertion Scale, scores from 12 to 13)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I includes some therapies, including sleep restriction therapy, stimulus control therapy, sleep hygiene education, relaxation and cognitive therapy\[19\]. Traditionally, CBT-I is applied in person (individually or in a group) by a trained psychologist or psychiatrist. However, several studies show similar effects when CBT-I is performed remotely, and online (digital)
Study: NCT06629103

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: life's Omega 1035DS
Description: A natural triglyceride derived from microalgae with minimum 365 mg DHA, minimum 100 mg EPA, and minimum 520 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
Study: NCT03974828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthesia Control Tower Notification
Description: Real-time data will be monitored through the AlertWatch system as well as the electronic health record. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthesia Control Tower Notification
Description: Real-time data will be monitored through the AlertWatch system as well as the electronic health record. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.
Study: NCT06629103

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Commercially available fish oil product MEG-3 1812 TG with a minimum 100 mg DHA/capsule, minimum 160 mg EPA/capsule, and minimum 300 mg/g DHA+EPA. Participants receive 600mg/d of omega-3 fatty acids from the fish oil.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will be a mixture of corn and soybean oils. Participants receive 600mg/d of omega-3 fatty acids from the corn/soy placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: life's Omega O3020DS
Description: A natural triglyceride derived from microalgae with minimum 210 mg DHA, minimum 300 mg EPA, and minimum 510 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
Study: NCT06271057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: golcadomide
Description: golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166
Study: NCT05913908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DUO Transcatheter Tricuspid Coaptation Valve System
Description: Reduction of tricuspid regurgitation through a transcatheter approach
Study: NCT04695847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1231
Description: M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1231
Description: M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1231
Description: M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
Study: NCT06031480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib and TQB2450
Description: Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent.
Study: NCT06266416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA for Black Male Caregivers and Girls Empowerment
Description: IMAGE is delivered by trained Black female facilitators to improve girls' SRH outcomes, prevention HIV/STIs, and reduce sexual violence. Over the two days, some components of the curriculum are delivered separately to male caregivers and girls, covering parallel content, and other sections are delivered jointly in a single group. The curriculum, extensively tailored for the target population and pilot tested, addresses Black girls' sexual development, risk for sexual violence, female anatomy, body positivity, HIV/STI knowledge and attitudes, and condom use. IMAGE is designed to strengthen bonds and communication between male caregivers and girls by encouraging perspective-taking (i.e., reverse role play) and conflict resolution.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-matched control program
Description: FUEL will engage Black male caregivers and girls to promote good nutrition, exercise, and informed consumer behavior. Topics include the impact of media on body image, evaluating nutritional labels to make healthy food choices, eating balanced meals, establishing regular exercise routines, and how families and communities can support healthy behavior. FUEL includes a brief video about HIV/AIDS and other STIs but otherwise does not otherwise address sexual health. Like IMAGE, FUEL is delivered in groups of 6-8 dyads over two workshop days (\~10 hours total) in one weekend. Parts of the curriculum are delivered separately to girls and male caregivers covering parallel content and other components are delivered jointly.
Study: NCT05915819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Training
Description: Exercise prescription according to weeks, sets and repetition. Weeks 1 and 2 1-2 sets / 10 repetitions Double leg jump Medicine ball(MB) stuffer flutter MB overhead throw MB single leg dip, Arrow cone drill Figure 8 drill Weeks 3 and 4 1-2 sets / 8 repetitions Ankle jumps Lateral cone hops Zigzag jump drill MB chest pass Jump \& turn 90° High-5 drill MB split squat Power skipping Clock drill T-drill Weeks 5 and 6 1-2 sets / 6 repetitions Dot drill Single leg cone hops Long jump and sprint Single leg zigzag drill MB lunge chest pass Jump and turn 180° Split squat jump Alternate bounding X-drill Shuttle drill
Study: NCT06434727

Intervention type: OTHER
Intervention: observational study
Description: Observational Study

Intervention type: OTHER
Intervention: observational study
Description: Observational Study
Study: NCT06546618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pictorial warning and no flavor
Description: LCC Package with pictorial warning and no flavor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pictorial warning and 'sweet' flavor
Description: LCC Package with pictorial warning and 'sweet' flavor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only warning and no flavor
Description: LCC Package with text-only warning and no flavor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only warning and 'sweet' flavor
Description: LCC Package with text-only warning and 'sweet' flavor